Analyst Price Targets — REPL
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 30, 2026 11:46 am | — | Wedbush | $9.00 | $11.20 | TheFly | Replimune price target raised to $9 from $6 at Wedbush |
| June 30, 2026 8:36 am | Evan Seigerman | BMO Capital | $16.00 | $11.20 | TheFly | Replimune upgraded to Outperform from Market Perform at BMO Capital |
| February 5, 2026 11:49 am | — | Piper Sandler | $14.00 | $7.00 | TheFly | Replimune price target raised to $14 from $13 at Piper Sandler |
| November 3, 2025 9:23 am | Evan Seigerman | BMO Capital | $11.00 | $9.73 | TheFly | Replimune upgraded to Market Perform from Underperform at BMO Capital |
| October 27, 2025 10:17 am | — | H.C. Wainwright | $12.00 | $8.80 | TheFly | Replimune upgraded to Buy from Neutral at H.C. Wainwright |
| October 20, 2025 1:05 pm | — | Wedbush | $18.00 | $9.15 | TheFly | Wedbush upgrades Replimune to Outperform amid second BLA review |
| January 22, 2025 2:41 pm | Evan Seigerman | BMO Capital | $27.00 | $13.09 | TheFly | Replimune price target raised to $27 from $18 at BMO Capital |
| December 3, 2024 8:58 pm | Roger Song | Jefferies | $19.00 | $14.48 | StreetInsider | Replimune Group (REPL) PT Raised to $19 at Jefferies |
| June 7, 2024 6:07 am | Robert Burns | H.C. Wainwright | $17.00 | $7.11 | TheFly | Replimune Group price target raised to $17 from $12 at H.C. Wainwright |
| June 4, 2024 9:51 am | Peter Lawson | Barclays | $13.00 | $5.37 | StreetInsider | Barclays Reiterates Overweight Rating on Replimune Group (REPL) |
Latest News for REPL
SAN DIEGO, July 15, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of current, long-term shareholders of Replimune Group, Inc. (NASDAQ: REPL) against certain of its officers and directors for alleged breaches of fiduciary duty.
Replimune Group, Inc. faces a pivotal FDA AdCom for RP1 after two prior rejections, with a final FDA approval decision expected August 2, 2026. RP1 demonstrated a 34% ORR and median overall survival of 32.9 months in anti-PD-1-failed melanoma, but trial design concerns persist. REPL stock has surged over 135% since April as FDA leadership changes and collaborative dialogue opened a path for BLA resubmission.
WOBURN, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for the fiscal fourth quarter and year ended March 31, 2026 and provided a business update.
WOBURN, Mass., June 26, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the Biologics License Application (BLA) for RP1 (vusolimogene oderparepvec) in combination with nivolumab for the…
Replimune stock surges after the company aligned with the FDA on plans to resubmit its BLA for RP1 plus Opdivo in advanced melanoma.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for REPL.
U.S. House Trading
No House trades found for REPL.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.